Baidu
map

Waston人工智能对医疗帮助有限?IBM回应质疑

2017-02-23 相海泉 健康界

MD安德森肿瘤中心中止了与IBM的合作,引发了对Waston人工智能于医疗帮助的质疑,IBM回应称,项目已取得初步成效。

2月21日,《科学》等媒体报道,全球顶级癌症研究与临床诊疗机构MD安德森肿瘤中心中止了与IBM Watson的人工智能合作项目,原因是涉及购买IBM Watson人工智能和深度学习技术的违规。



有媒体藉此对Watson进入临床应用的进程表示担忧,并对Watson人工智能在医疗领域的表现提出质疑。

健康界获悉了IBM对该事件的官方声明,声明称“报告所描述的结果是基于采购活动文件和工作人员的相关说词,不应被视为对Watson项目现阶段系统的科学基础或功能方面的评价。”

声明还表示,Watson在与世界上多个医疗机构合作的项目均显示出有效性,“IBM Watson将继续与全球越来越多的医疗专家合作,进一步加深人们对Watson的认识,并将这项前沿科技推广给更多的医生及其病人,从而在与癌症斗争中尽一份力。”

因经济问题中止合作

此次中止合作涉及购买IBM Watson人工智能和深度学习技术的违规。

MD安德森肿瘤中心和IBM Watson深度学习大数据项目始于2013年,主题是“大数据人工智能应用将加速对癌症疾病的认知和完善癌症临床治疗”,该项目由MD安德森肿瘤中心Ronald DePinho院长夫人Lynda Chin(知名肿瘤专家)。

媒体报道称,在未明确Watson人工智能深度学习能力的前提下,MD安德森肿瘤中心全额支付了IBM 6210万美元研发费用。业内人士分析,诸如此类的合作开发项目,MD安德森肿瘤中心完全占据优势,可以依靠其雄厚的临床研究资源和国际品牌效应,事先支付相关研发费用或知识产权费用有悖常理。

在这项合作中,Lynda Chin显然是焦点,因为许多资金和费用安排都由其协调。而该项目资金的投入,其中5000万美元来自被认为非常喜欢炫耀的马来西亚投资大亨Low Taek Jho(资金至今未到位),由此引起了美国司法部对该项目资金的来龙去脉的关注和审计。

引发对IBM Watson人工智能的质疑

虽然此事肇始于经济问题,但媒体仍对IBM Watson人工智能对医疗的帮助提出质疑。

有媒体称,MD安德森肿瘤中心和IBM合作开发Watson深度学习项目,辅助诊断肿瘤疾病并未披露中期临床效果。

甚至有业内人士质疑:“IBM Watson深度学习能力究竟帮上多少忙?还是医生在帮Watson的忙?”

IBM回应:项目已取得初步成功

在IBM的回应声明中,一开始就表示与MD安德森肿瘤中心的合作“证明了Watson在医学上的成功应用”。

声明称:“美国MD安德森肿瘤中心的肿瘤学家和研究员评价Watson所给的建议治疗方案有90%的准确率。这种高准确率能帮助肿瘤科医生确保他们在做癌症诊疗与诊断时不会错失任何关键数据。”该中心的医生对Watson能力表示认可。

“由于Watson研发项目已取得了初步成功,如果美国安德森肿瘤中心选择继续推进Watson研发,那么该项目将发展更深且更广的应用。”

声明特别强调:“本报告所描述的结果是基于采购活动文件和工作人员的相关说词,不应被视为对Watson项目现阶段系统的科学基础或功能方面的评价。”并列举了IBM Watson与世界上多个医疗机构合作的情况,“十多个相关研究显示Watson能协助医生更有效率地制定医疗决策并进而影响患者”。

声明在最后称,IBM Watson将继续与全球越来越多的医疗专家合作,进一步加深人们对Watson的认识,并将这项前沿科技推广给更多的医生及其病人,从而在与癌症斗争中尽一份力。

以下为声明全文:

IBM Statement on UT Report on MD Anderson

The University of Texas Administration recently recently published a review of procurement practices related to this program (“Special Review of Procurement Procedures Related to the M.D. Anderson Cancer Center Oncology Expert Advisor Project”). The report was focused on MD Anderson practices and did not assess the value or functionality of the OEA system. As stated in the report’s executive summary, "results stated herein are based on documented procurement activities and recollections by staff, and should not be interpreted as an opinion on the scientific basis or functional capabilities of the system in its current state."IBM is working with multiple partners in the fight against cancer. In just a few short years, Watson for Oncology has helped more than 12,000 patients.

For example, IBM’s work Memorial Sloan Kettering Cancer Center resulted in a commercialized offering that is now in use, helping doctors to personalize cancer care in India, China, Korea and the United States.

Working with experts at Manipal Hospitals in India, Watson for Oncology achieved 90 percent concordance with the hospital’s tumor board.

And just this month, Jupiter Medical Center became the first community hospital in U.S. to adopt IBM Watson for Oncology, which is now available to doctors treating breast, lung, colorectal, gastric, cervical and ovarian cancers.

Doctors’ positive, real-world experience with Watson for Oncology is underscored by a growing body of clinical evidence. More than a dozen early studies demonstrate the efficacy of Watson in supporting physicians’ decision making and the impact on patients, including data recently presented at the 2016 San Antonio Breast Cancer Symposium. More evidence will be presented this year at the ASCO Annual Meeting.

We will continue to partner with more and more healthcare experts across the globe to deepen Watson’s understanding and help bring this technology to more physicians and their patients battling cancer.

本文部分内容来自微信公众号“全球医生组织”。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1710977, encodeId=be821e1097701, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Apr 04 04:41:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984755, encodeId=2a5c1984e5565, content=<a href='/topic/show?id=abbb1861586' target=_blank style='color:#2F92EE;'>#Waston#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18615, encryptionId=abbb1861586, topicName=Waston)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Oct 04 18:41:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735094, encodeId=cd3d1e3509492, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sat Jan 20 11:41:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489932, encodeId=463c1489932e9, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sat Feb 25 02:41:00 CST 2017, time=2017-02-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1710977, encodeId=be821e1097701, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Apr 04 04:41:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984755, encodeId=2a5c1984e5565, content=<a href='/topic/show?id=abbb1861586' target=_blank style='color:#2F92EE;'>#Waston#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18615, encryptionId=abbb1861586, topicName=Waston)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Oct 04 18:41:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735094, encodeId=cd3d1e3509492, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sat Jan 20 11:41:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489932, encodeId=463c1489932e9, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sat Feb 25 02:41:00 CST 2017, time=2017-02-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1710977, encodeId=be821e1097701, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Apr 04 04:41:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984755, encodeId=2a5c1984e5565, content=<a href='/topic/show?id=abbb1861586' target=_blank style='color:#2F92EE;'>#Waston#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18615, encryptionId=abbb1861586, topicName=Waston)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Oct 04 18:41:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735094, encodeId=cd3d1e3509492, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sat Jan 20 11:41:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489932, encodeId=463c1489932e9, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sat Feb 25 02:41:00 CST 2017, time=2017-02-25, status=1, ipAttribution=)]
    2018-01-20 saikp
  4. [GetPortalCommentsPageByObjectIdResponse(id=1710977, encodeId=be821e1097701, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Apr 04 04:41:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984755, encodeId=2a5c1984e5565, content=<a href='/topic/show?id=abbb1861586' target=_blank style='color:#2F92EE;'>#Waston#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18615, encryptionId=abbb1861586, topicName=Waston)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Oct 04 18:41:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735094, encodeId=cd3d1e3509492, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sat Jan 20 11:41:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489932, encodeId=463c1489932e9, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sat Feb 25 02:41:00 CST 2017, time=2017-02-25, status=1, ipAttribution=)]
    2017-02-25 tulenzi

相关资讯

当人工智能遇上了医疗,碰撞出哪些火花?

人工智能“学会”诊断皮肤癌英国《自然》杂志24日在线发表的一篇癌症相关研究论文,描述了一种利用深度学习算法来根据照片分类皮肤癌的人工智能(AI)系统,表现不亚于专业临床医生。这项研究突出展示了人工智能支持、简化和扩展皮肤癌诊断的潜力。皮肤癌是最为常见的人类恶性肿瘤,病因迄今不明。其根据肿瘤细胞的来源不同而有不同的分型,包括表皮、皮肤附属器、皮肤软组织、周围神经、黑素细胞、皮肤淋巴网状组织和造血

刘继兰:HIMSS2017将重点关注人群健康、人工智能和信息安全

HIMSS2017全球年会有哪些热点?对于国内的医疗信息化建设有何启示?

Nature:美学者报道人工智能准确诊断皮肤癌

2017年2月2日,国际学术权威刊物自然出版集团《Nature》杂志在线发表了美国斯坦福大学Sebastian Thrun研究员的一篇研究论文,研究表示将来一款简单的手机 app 就可以帮助患者自己诊断皮肤癌——美国当前最常见的癌症。

11家医疗人工智能公司“抢跑”吸金 4大特点势不可挡

人工智能现在是各个领域最火的创业方向,包括医疗。近期我们甚至看到百度全面放弃了从互联网进入医疗的尝试,而全面转向人工智能方向。然而,人工智能除了展现出无限的想象空间外,其实仍然带有非常多的不确定性。这里参考CBinsight、crunchbase的数据,整理了来自全球的11家人工智能方面的医疗创业公司,包括他们的创始人、应用方向以及投融资情况。这几个维度也是目前能够评判一家初创公司的重要维度。

Nature封面重磅:人工智能一出马,人类医生就败下阵来

皮肤癌是人类最为常见的恶性肿瘤之一。皮肤癌与往往因为与痣长得过于相像,而被忽略。等到病情恶化时,则已经为时过晚。上周,发表在《自然》(Nature)杂志上的一篇论文给我们提供了一项方便的工具。而它的背后,则是现在火爆得不行的深度学习和人工智能。

机器学习专题:人工智能的黄金时代

近日,《自然》子刊《Nature Biomedical Engineering》推出了“机器学习”特刊,为我们介绍了机器学习在医疗领域的广泛应用。我们今日也推出“机器学习”专题,将这些信息整理给读者。

Baidu
map
Baidu
map
Baidu
map